Associated tags: Genetics, Patient, Histology, MDM2, RAD52, Therapy, Cancer, Pharmaceutical industry, RAIN, Security (finance), Liposarcoma, LPS, Food, Merkel-cell carcinoma, Conference, Webcast, Safety
Locations: RAIN
FDA,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
U.S. Securities and Exchange Commission,
IO,
Association,
Histology,
American Association,
Accounting,
GLOBE,
R,
Population,
Annual general meeting,
Private Securities Litigation Reform Act,
RAIN,
Investment,
Clinical trial,
MANTRA,
Security (finance),
RAD52,
MDM2,
Patient,
Therapy,
COVID-19,
Prognosis,
International,
Program,
American Association for Cancer Research,
Liposarcoma,
ICI,
Safety,
G&A,
AACR,
Research,
Nasdaq,
Webcast,
CDKN2A,
Merkel-cell carcinoma,
Genetics,
LPS,
Food,
Health,
Pharmaceutical industry NEWARK, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today reported financial results for the second quarter and six months ended June 30, 2022, along with an update on the Company’s key developments, business operations and upcoming milestones.
Key Points:
- As of June 30, 2022, Rain had $105.7 million in cash, cash equivalents and short-term investments.
- Rain anticipates that its quarter-end cash position will provide runway into mid-2024 and therefore believes the milademetan program is well-funded.
- As of June 30, 2022, Rain had approximately 26.5 million shares of common stock outstanding.
- The management of Rain Therapeutics will host a conference call and webcast for the investment community today, August 4, 2022 at 2:00 pm PT (5:00 pm ET).
WESTON, Fla., Aug. 04, 2022 (GLOBE NEWSWIRE) -- The Black Knight Satellite Album was released alongside the documentary "The Black Knight Satellite, Beyond the Signal" written and directed by Melissa Tittl and executive produced by President/CEO of 4biddenknowledge Inc. Billy Carson.
Key Points:
- WESTON, Fla., Aug. 04, 2022 (GLOBE NEWSWIRE) -- The Black Knight Satellite Album was released alongside the documentary "The Black Knight Satellite, Beyond the Signal" written and directed by Melissa Tittl and executive produced by President/CEO of 4biddenknowledge Inc. Billy Carson.
- This album quickly gained popularity for its knowledge-based songs and extraordinary features on the tracks.
- The Black Knight Satellite album has been out now for two months and has made the Amazon best-selling music chart, competing with albums by Snoop Dogg, Kevin Gates, and Eminem.
- Investors looking to be part of this rapidly expanding business can find more information about this investment opportunity by following the link below.
Private Securities Litigation Reform Act,
Orphan,
Security (finance),
Population,
CDKN2A,
Standard of care,
Bachelor of Medicine, Bachelor of Surgery,
Cancer,
Patient,
Food,
Review,
U.S. Securities and Exchange Commission,
Progression-free survival,
Safety,
FDA,
Trabectedin,
Extremities,
MANTRA,
Nasdaq,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Therapy,
PFS,
MDM2,
Genetics,
GLOBE,
LPS,
Histology,
Liposarcoma,
Merkel-cell carcinoma,
RAIN,
WD,
Incidence,
RAD52,
ICI,
Pharmaceutical industry,
Medicine NEWARK, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced completion of enrollment in its Phase 3 MANTRA randomized, global, registrational trial of its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53. The trial targeted an enrollment of 160 patients and completed enrollment five months ahead of schedule with 175 patients.
Key Points:
- The trial targeted an enrollment of 160 patients and completed enrollment five months ahead of schedule with 175 patients.
- MANTRA is an event-driven trial with progression-free survival (PFS) as the primary endpoint, which will be analyzed upon reaching 105 events.
- The MANTRA trial is powered to show a doubling of PFS versus the standard of care.
- Milademetan is being evaluated in an ongoing Phase 3 clinical trial in patients with LPS (MANTRA), as well as a Phase 2 tumor-agnostic basket trial in certain solid tumors (MANTRA-2).
MANTRA,
MDM2,
RAD52,
U.S. Securities and Exchange Commission,
Investment,
Private Securities Litigation Reform Act,
GLOBE,
Liposarcoma,
Accounting,
Company,
Nasdaq,
ICI,
Safety,
Food,
Research,
Patient,
Histology,
Security (finance),
Webcast,
FDA,
International,
Therapy,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
LPS,
CDKN2A,
R,
RAIN,
Genetics,
Merkel-cell carcinoma,
G&A,
Cancer,
Fine chemical,
Pharmaceutical industry Rain continues to make strong progress in its ongoing milademetan trials, with topline data from the Phase 3 MANTRA liposarcoma trial now anticipated in the first half of 2023.
Key Points:
- Rain continues to make strong progress in its ongoing milademetan trials, with topline data from the Phase 3 MANTRA liposarcoma trial now anticipated in the first half of 2023.
- As of March 31, 2022, Rain had $123.2 million in cash, cash equivalents and short-term investments.
- As of March 31, 2022, Rain had approximately 26.5 million shares of common stock outstanding.
- The management of Rain Therapeutics will host a conference call and webcast for the investment community today, May 4, 2022 at 2:00 pm PT (5:00 pm ET).
Private Securities Litigation Reform Act,
CDKN2A,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Therapy,
Patient,
Investment,
G&A,
PD-L1,
MCC,
RAD52,
Genetics,
Accounting,
ICI,
Food,
Security (finance),
Safety,
U.S. Securities and Exchange Commission,
Roche,
Liposarcoma,
FDA,
Webcast,
Orphan,
Company,
Cancer,
RAIN,
Phase 3,
LPS,
Histology,
Merkel-cell carcinoma,
MDM2,
GLOBE,
Nasdaq,
Pharmaceutical industry,
Fine chemical NEWARK, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today reports financial results for the fourth quarter and full year ended December 31, 2021, along with an update on the Company's key developments, business operations and upcoming milestones.
Key Points:
- Rain has achieved a number of important clinical milestones for milademetan including commencing two of the four planned trials in MDM2-dependent cancers.
- Global site activations exceeded the target for year-end 2021, and all sites anticipated to be activated by the end of the first quarter of 2022.
- Rain dosed the first patient in its multicenter, open-label Phase 2 basket trial (MANTRA-2) in November 2021, evaluating milademetan in MDM2-amplified advanced solid tumors.
- Rain made significant progress in site activations for MANTRA-2 and anticipates all sites will be activated by the end of the first quarter of 2022.
Retrieved on:
Friday, November 19, 2021
Patient,
Private Securities Litigation Reform Act,
Merkel-cell carcinoma,
Security (finance),
Nasdaq,
Safety,
Cancer,
Liposarcoma,
RECIST,
Clinical trial,
RAD52,
Gene amplification,
Progression-free survival,
U.S. Securities and Exchange Commission,
Therapy,
RAIN,
MANTRA,
Genetics,
GLOBE,
LPS,
Histology,
MDM2,
FDA,
Bachelor of Medicine, Bachelor of Surgery,
ICI,
Food,
Pharmaceutical industry,
Medical imaging NEWARK, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced that the first patient has been dosed in the multicenter, single arm, open-label, Phase 2 basket trial evaluating milademetan, an oral mouse double minute 2 (MDM2) inhibitor, for the treatment ofMDM2-amplified advanced solid tumors.
Key Points:
- NEWARK, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced that the first patient has been dosed in the multicenter, single arm, open-label, Phase 2 basket trial evaluating milademetan, an oral mouse double minute 2 (MDM2) inhibitor, for the treatment ofMDM2-amplified advanced solid tumors.
- The Rain team has worked extraordinarily hard to now commence our second clinical trial for milademetan, said Avanish Vellanki, chief executive officer of Rain Therapeutics.
- The MANTRA-2 trial is designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-caretherapyand that exhibitwild-type p53 and a prespecified minimum MDM2 gene copy number.
- Milademetan is being evaluated in an ongoing Phase 3 clinical trial in patients with LPS (MANTRA), as well as a Phase 2 tumor-agnostic basket trial in certain solid tumors (MANTRA-2).
Retrieved on:
Wednesday, November 10, 2021
Compliance,
Histology,
MCC,
Private Securities Litigation Reform Act,
G&A,
Therapy,
Genetics,
Clinical trial,
Therapeutic index,
R,
Security (finance),
Dana–Farber Cancer Institute,
RAD52,
Food,
Investment,
Merkel-cell carcinoma,
COVID-19,
RAIN,
Research,
Cancer,
AACR,
Conference,
Company,
U.S. Securities and Exchange Commission,
GLOBE,
MANTRA,
LPS,
SEC,
MDM2,
Webcast,
Accounting,
Patient,
Liposarcoma,
Nasdaq,
ICI,
Fine chemical,
Medical device,
Pharmaceutical industry,
Animal,
Cryptocurrency NEWARK, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today reports financial results for the third quarter and nine months ended September 30, 2021, along with an update on the company's key developments, business operations and upcoming milestones.
Key Points:
- The Phase 2 MCC clinical trial will replace the previously planned Phase 2 clinical trial of milademetan in intimal sarcoma.
- As of September 30, 2021, Rain had $150.1 million in cash, cash equivalents and short-term investments.
- The management of Rain Therapeutics will host a conference call and webcast for the investment community today, November 10, 2021, at 1:30 p.m. PT (4:30 p.m.
- A live webcast may be accessed by visiting the Investors section of the Rain Therapeutics website at www.rainthera.com .
Retrieved on:
Tuesday, November 9, 2021
Histology,
Population,
Safety,
MCC,
Cancer,
Nasdaq,
Private Securities Litigation Reform Act,
Therapy,
Genetics,
Security (finance),
RAD52,
Food,
Trial of the century,
Merkel-cell carcinoma,
RAIN,
Program,
ICI,
AACR,
Neoplasm,
Incidence,
U.S. Securities and Exchange Commission,
GLOBE,
Conference,
MANTRA,
LPS,
MDM2,
ORR,
Interest,
Patient,
Liposarcoma,
RECIST,
Ageing,
Lists of people executed in the United States,
Pharmaceutical industry NEWARK, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced its plan to commence a Phase 2 clinical trial, named MANTRA-3, evaluating the efficacy of milademetan, an oral mouse double minute 2 (MDM2) inhibitor, as a monotherapy for the treatment of patients with Merkel cell carcinoma (MCC) refractory to immune checkpoint inhibition (ICI) in mid-2022.
Key Points:
- We are very excited about the recent preclinical data generated for milademetan in Merkel cell carcinoma, and believe the data warrant moving the program into a clinical study, said Avanish Vellanki, co-founder and chief executive officer of Rain.
- Rain will prioritize its financial resources towards a Phase 2 clinical trial of milademetan in MCC and replace the previously planned Phase 2 clinical trial of milademetan in intimal sarcoma.
- Merkel cell carcinoma is a rare, aggressive type of skin cancer that frequently travels to other parts of the body.
- Rain Therapeutics also anticipates commencing a Phase 2 clinical trial of milademetan (MANTRA-3), for the treatment of patients with Merkel cell carcinoma refractory to immune checkpoint inhibition (ICI), in mid-2022.
Retrieved on:
Wednesday, November 3, 2021
MDM2,
Histology,
Cancer,
RAD52,
Conference,
Therapy,
Patient,
GLOBE,
Nasdaq,
Webcast,
RAIN,
Genetics,
Pharmaceutical industry NEWARK, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the third quarter that ended September 30, 2021 and highlights of recent progress, on Wednesday, November 10, 2021.
Key Points:
- NEWARK, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the third quarter that ended September 30, 2021 and highlights of recent progress, on Wednesday, November 10, 2021.
- On that day, management will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m.
- Rains lead product candidate, milademetan (RAIN-32), is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers.
- In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
KOL,
Breast cancer,
Cancer,
Memorial Sloan Kettering Cancer Center,
Neoplasm,
Brown University,
Histology,
MD Anderson Cancer Center,
LPS,
Security (finance),
U.S. Securities and Exchange Commission,
Patient,
Private Securities Litigation Reform Act,
RAIN,
Liposarcoma,
MDM2,
Center,
Lists of people executed in the United States,
RAD52,
Hematology-Oncology and Stem Cell Transplantation Research Center,
University,
Research and development,
Clinical trial,
Webcast,
Roswell Park Comprehensive Cancer Center,
DD,
R,
Oncology,
Therapy,
National Cancer Institute,
Q&A,
GLOBE,
Division,
Doctor of Philosophy,
Nasdaq,
Department,
Genetics,
Management,
Medical imaging,
Vaccine,
Pharmaceutical industry NEWARK, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced that it will host a virtual Research and Development (R&D) day on Tuesday, November 9, 2021 from 11:00 am to 2:00 pm Eastern Time.
Key Points:
- NEWARK, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced that it will host a virtual Research and Development (R&D) day on Tuesday, November 9, 2021 from 11:00 am to 2:00 pm Eastern Time.
- We are excited to share a detailed update on our plans for milademetan in our inaugural R&D day, saidAvanish Vellanki, co-founder and chief executive officer of Rain.
- We look forward to hosting several KOLs in oncology to discuss the potential opportunity in various MDM2-dependent patient populations.
- The webcast will also be available under the Events and Presentations section of the Rain website.
